Production of "ectopic" vasoactive intestinal peptide-like and neurotensin-like immunoreactivity in human pheochromocytoma cell cultures

Tischler, A. S.; Lee, Gary; Perlman, R.L.; Costopoulos, Donna; Slayton, VW; Bloom, S.R.

doi:10.1523/jneurosci.04-05-01398.1984

Cited by 33 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumours of the lung (SCLC), MTC, phaeochromocytoma and NETs arising from the kidney have also been reported to produce VIP (Said & Faloona 1975, Tischler et al 1984. Calcitonin gene related peptide (CGRP) is derived from the calcitonin gene as a result of alternative processing of calcitonin mRNA; this is widely distributed in the thyroid and neural tissues of brain, gut and perivascular tissue (Herrera et al 1992), whereas VIP is the major product in the central and peripheral nervous system (Herrera et al 1992).…”

Section: Ectopic Gut Hormonal and Vasoactive Peptide Secretionmentioning

confidence: 99%

Paraneoplastic syndromes secondary to neuroendocrine tumours

Kaltsas

Androulakis²,

Herder³

et al. 2010

Endocrine-Related Cancer

View full text Add to dashboard Cite

Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes. The term 'paraneoplastic syndromes' (PNSs) is used to denote syndromes secondary to substances secreted from tumours not related to their specific organ or tissue of origin and/or production of autoantibodies against tumour cells; such syndromes are mainly associated with hormonal and neurological symptoms. Appreciation of the presence of such syndromes is important as clinical presentation, if not identified, may delay the diagnosis of the underlying neoplasia. Conversely, early recognition can allow for more rapid diagnosis, particularly as the coexistence of a neoplasm with a clinical or biochemical marker offers an additional determinant of tumour status/progression. PNSs can complicate the patient's clinical course, response to treatment, impact prognosis and even be confused as metastatic spread. Their diagnosis involves a multidisciplinary approach, and detailed endocrinological, neurological, radiological and histological studies are required. Correct diagnosis is essential as the treatment of choice will be different for each disorder, particularly in the case of malignant tumours; it is therefore important to develop appropriate means to correctly identify and localise these tumours. Clinical awareness and the incorporation into clinical practise of 111 In-octreotide scintigraphy, chromogranin A and other evolving biochemical marker measurement techniques have substantially contributed to the identification of patients harbouring such syndromes. Diseasespecific medical therapies are mandatory in order to prevent recurrence and/or further tumour growth. Owing to their rarity, central registration of these syndromes is very helpful in order to be able to provide evidence-based diagnostic and therapeutic approaches.

show abstract

Section: Ectopic Gut Hormonal and Vasoactive Peptide Secretionmentioning

confidence: 99%

Paraneoplastic syndromes secondary to neuroendocrine tumours

Kaltsas

Androulakis²,

Herder³

et al. 2010

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Ndel1/EOPA, is a thiol-sensitive enzyme inactivates physiologically important peptides such as bradykinin and neurotensin, and also converts opioid oligopeptides into enkephalins (Camargo et al, 1973(Camargo et al, , 1983(Camargo et al, , 1987Gomes et al, 1993;Hayashi et al, 2000. The contribution of bradykinin and neurotensin neuropeptides in neurite outgrowth was also previously described (Zhao et al, 2003;Tischler et al, 1991;Robson and Burgoyne, 1989;Tischler et al, 1984).…”

Section: Lis1 and Ndel1: Microtubule Associated Proteins Involved In mentioning

confidence: 87%

Gene Expression in Embryonic Neural Development and Stem Cell Differentiation

Chang¹,

Vieceli²,

Kanno³

et al. 2012

Embryogenesis

View full text Add to dashboard Cite

“…Cases of vasoactive intestinal polypeptide (VIP) secretion causing typical watery diarrhoea has been described secondary to SCLC, MTC, phaeochromocytoma and NETs arising from the kidney (Said & Faloona 1975, Tischler et al 1984. Glucagonlike peptides (GLP) 1 and 2 are hormones derived from the post-translational processing of pro-glucagon in the intestinal L cells that influence intestinal motility and small bowel growth, respectively.…”

Section: Less Common Endocrine Pns Secondary To the Secretion Of Peptmentioning

confidence: 99%

Paraneoplastic endocrine syndromes

Dimitriadis

Angelousi

Weickert

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

The majority of neoplasms are responsible for symptoms caused by mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic syndromes when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin. Endocrine paraneoplastic syndromes can complicate the patient's clinical course, response to treatment, impact prognosis and even be confused as metastatic spread. These syndromes can precede, occur concomitantly or present at a later stage of tumour development, and along with the secreted substances constitute the biological 'fingerprint' of the tumour. Their detection can facilitate early diagnosis of the underlying neoplasia, monitor response to treatment and/or detect early recurrences following successful initial management. Although when associated with tumours of low malignant potential they usually do not affect long-term outcome, in cases of highly malignant tumours, endocrine paraneoplastic syndromes are usually associated with poorer survival outcomes. Recent medical advances have not only improved our understanding of paraneoplastic syndrome pathogenesis in general but also enhanced their diagnosis and treatment. Yet, given the rarity of endocrine paraneoplastic syndromes, there is a paucity of prospective clinical trials to guide management. The development of well-designed prospective multicentre trials remains a priority in the field in order to fully characterise these syndromes and provide evidence-based diagnostic and therapeutic protocols.

show abstract

Production of "ectopic" vasoactive intestinal peptide-like and neurotensin-like immunoreactivity in human pheochromocytoma cell cultures

Cited by 33 publications

References 18 publications

Paraneoplastic syndromes secondary to neuroendocrine tumours

Paraneoplastic syndromes secondary to neuroendocrine tumours

Gene Expression in Embryonic Neural Development and Stem Cell Differentiation

Paraneoplastic endocrine syndromes

Contact Info

Product

Resources

About